South Carolina Restricts Research-Grade Peptides and Compounding Powders

Patient consent waivers will not protect clinics using non-FDA-approved active ingredients.

The South Carolina Board of Medical Examiners issued a formal notice on August 18, 2026, warning against and strictly restricting the use of research-grade, non-FDA-approved peptides and raw compounding powders in patient care. This decision directly impacts practices offering medical weight loss and wellness therapies, particularly those utilizing semaglutide and semaglutide salt forms. Under the new directive, physicians are explicitly prohibited from compounding, administering, dispensing, prescribing, recommending, or delegating the use of these "research-grade" substances to Advanced Practice Registered Nurses (APRNs) or Physician Assistants (PAs).

To remain compliant, South Carolina practices must source all prescription drugs and compounded drug ingredients exclusively from facilities permitted by the South Carolina Board of Pharmacy. Utilizing unauthorized wholesale channels or unapproved raw powders puts medical licenses at immediate risk, as the medical board warns that providers violating these rules will face professional discipline. Furthermore, the board clarified a critical legal point for business owners: patient consent forms or liability waivers that identify a product as "research-grade" do not shield a provider from professional or legal liability.

If you operate in South Carolina, or if your state board typically follows these regulatory trends, you must audit your inventory immediately. Ensure your sourcing for ingredients like semaglutide is fully vetted through board-permitted pharmacies, and discontinue any reliance on patient waivers to justify the use of non-clinical ingredients.

Source: American Med Spa Association, https://www.americanmedspa.org/news/south-carolina-medical-board-warns-against-use-of-research-grade-peptides